BioWorld

July 23, 2008

$125M Deal Sends Mirus Bio Into the Roche RNAi Camp

Roche Holding AG, fresh off its $44 billion offer for Genentech Inc., moved to accelerate its research into RNAi gene silencing technology with the acquisition of Mirus Bio Corp. for $125 million. (BioWorld Today) Read More

BioMarin, Summit Partner for Duchenne Drug in $143M Deal

Biogen's Strong 2nd Quarter Helped by Tysabri Sales

Depomed Gets $12M Up Front in Diabetes Deal with Santarus

Other News To Note

Clinic Roundup

Appointments And Advancements

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...